ERBB2 and breast cancer: Of note, as AAV transgene expression has been reported to persist for years in primates and humans, this approach has been suggested as a potential additional part of the adjuvant therapy with the aim to prevent CNS recurrences for patients with early diagnosis of HER2-positive BC [208].